Glioblastoma is a aggressive brain cancer known for its rapid growth and insensitivity to typical treatments. Studies are constantly underway to identify new therapeutic strategies, and recently, a new biomarker named LCA168 has emerged as a potential target for GBM treatment. LCA168 is a protein that is abundantly produced in glioblastoma cells c